Table 1 The advantages and disadvantages in stem cell transplantation and in vivo cell reprograming for cardiac fibrosis therapy
From: Harnessing stem cell and lineage reprogramming technology to treat cardiac fibrosis
Therapy pathway | Advantages | Disadvantages | References |
|---|---|---|---|
Stem cell transplantation | 1). Diverse sources of stem cells 2). Precision therapy of injury heart 3). Exhibits a dose-dependent function 4). Induce both muscularization and vascularization in the injured heart | 1). Immune rejection 2). Biosafety concerns 3). Adverse cardiac effects (e.g., arrhythmias) 4). Low immaturity of transplanted cardiac myocytes 5). Low retention rate of transplanted cells | Lou et al. 2023 Querdel et al. 2021 Gao et al. 2018 Liu et al. 2018 |
In vivo Cell reprograming | 1). In situ repair of the injured heart 2). Cardiac fibroblast-specific 3). Reduce cardiac fibrosis and generate new cardiomyocytes in the same time | 1). Low efficiency and high cost 2). Biosafety concerns 3). Technical complexity 4). Emerging mutability | Tang et al. 2022 Garry et al. 2021 Muraoka et al. 2019 Miyamoto et al. 2018 |